Matinas BioPharma director gets 5,000 stock options

The option vests in full at the earlier of the one-year anniversary or a defined Change in Control, subject to continued service.

Available on EDGAR 11/06/2026 - 06:27 PM EST Accepted by SEC EDGAR 11/06/2026 - 06:23 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Matinas BioPharma Holdings, Inc. director Edward Neugeboren received a grant of an option to purchase 5,000 common shares on November 6, 2026, at a $1.16 exercise price. After the grant, his reported option position was 5,000 options. The options expire November 6, 2036, and vest in full upon the earlier of the one-year anniversary of the grant date or a Change in Control, subject to his continued service through the applicable vesting date.

Insider Trade Summary

Grant/Award: 5,000 shares

Grant/Award 1 txn

Insider NEUGEBOREN EDWARD

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to Buy) F1	5,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to Buy) — 5,000 contracts (Direct)

Holdings Before and After: Stock Option (right to Buy), 0 to 5,000 contracts (Direct)

Footnotes (1)

1. F1. On November 6, 2026 (the "Grant Date"), the Reporting Person was granted an option to purchase 5,000 shares of the Issuer's common stock, par value $.0001 per share, pursuant to the Issuer's 2025 Equity Incentive Plan (the "Plan"). The option will vest in full upon the earlier of (i) the one-year anniversary of the Grant Date or (ii) a "Change in Control" (as defined by the Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date.

Key Figures

Options granted: 5,000 options Exercise price: $1.16 per share Underlying common shares: 5,000 shares +2 more

5 metrics

Options granted 5,000 options Granted November 6, 2026

Exercise price $1.16 per share Option to purchase Matinas BioPharma Holdings common stock

Underlying common shares 5,000 shares Shares purchasable under the option

Vesting anniversary One year One of the earlier-of vesting triggers

Option expiration November 6, 2036 Expiration date

Key Terms

Change in Control, vesting, 2025 Equity Incentive Plan

3 terms

Change in Control technical

"a "Change in Control" (as defined by the Plan)"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

vesting financial

"will vest in full upon the earlier of"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

2025 Equity Incentive Plan financial

"pursuant to the Issuer's 2025 Equity Incentive Plan"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many MTNB shares can Edward Neugeboren's option purchase, and what is the exercise price?

Edward Neugeboren received an option to purchase 5,000 common shares at an exercise price of $1.16 per share.

When does Edward Neugeboren's MTNB option vest?

The option vests in full upon the earlier of the one-year anniversary of the November 6, 2026 grant date or a Change in Control, subject to his continued service through the applicable vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

NEUGEBOREN EDWARD

(Last) (First) (Middle)

C/O MATINAS BIOPHARMA HOLDINGS, INC.

1545 ROUTE 206 SOUTH SUITE 302

(Street)

BEDMINSTER NEW JERSEY 07921

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Matinas BioPharma Holdings, Inc. [ MTNB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to Buy)	$1.16	11/06/2026		A		5,000		(1)	11/06/2036	Common Stock	5,000	$0	5,000	D

Explanation of Responses:

1. On November 6, 2026 (the "Grant Date"), the Reporting Person was granted an option to purchase 5,000 shares of the Issuer's common stock, par value $.0001 per share, pursuant to the Issuer's 2025 Equity Incentive Plan (the "Plan"). The option will vest in full upon the earlier of (i) the one-year anniversary of the Grant Date or (ii) a "Change in Control" (as defined by the Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date.

	/s/ Jerome D. Jabbour, attorney-in fact for Edward Neugeboren	11/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)